Product Images Nabumetone

This is a description of Nabumetone tablets which are a generic version of the medication Relafen. Each tablet contains 500mg of the active ingredient. The tablets are available in a bottle of 60. The manufacturer is R Glenmark Generics. Patients taking these tablets may experience dizziness or drowsiness and should avoid alcohol. It is recommended to take the tablets with food. The dosing frequency is indicated as a blank space where the number of tablets and times per day should be filled in by the prescribing physician.*

COOH and CH40 are not recognizable text, so a useful description cannot be provided. However, "6-methoxy-2-naphthylacetic acid (6MNA)" is recognizable and could be used as a chemical name in a scientific context.*

This text appears to be a list of symptoms that may indicate various health conditions. These symptoms include nausea, tiredness or weakness, itching, yellowing of the skin or eyes, stomach pain, flu-like symptoms, vomiting blood, blood in bowel movements or tar-like stools, unusual weight gain, skin rash or blisters with fever, and swelling of the limbs and hands. It is important to seek medical attention if experiencing any of these symptoms, as they may indicate serious health conditions.*

This text appears to be a list of symptoms that may indicate a medical emergency. These include shortness of breath or difficulty breathing, slurred speech, chest pain, and swelling of the face or throat. Another symptom listed is weakness in one part or side of the body, which could also indicate a serious medical issue. It is important to seek medical attention immediately if experiencing any of these symptoms.*

The graph shows the plasma concentrations of the active metabolite (6MNA) of Nabumetone at steady state following once-daily doses of either 1000mg or 2000mg. The y-axis represents the concentration of 6MNA (ng/mL) and the x-axis represents the time in hours. The blue line represents patients who were given 1000mg of Nabumetone (n=31), while the orange line represents patients who were given 2000mg of Nabumetone (n=12). The shaded areas represent two standard deviations from the mean concentration. No other information is available from the text.*

This is a list of different forms in which nabumetone and its metabolites are found in the body after consumption. It includes the percentage of the total dose of each form present, ranging from not detectable to 73%.*

This text provides a list of generic names and corresponding trade names for various pain medications, including Celebrex, Cataflam, Voltaren, Dolobid, Lodine, Nalfon, Ansaid, Motrin, Indocin, Oruvail, Toradol, and Ponstel.*

This is a list of names of various types of pain relievers. Some of the names include Meloxicam, Nabumetone, Naproxen, Oxaprozin, Piroxicam, and Sulindac. There are also several types of medications listed under Naproxen, such as Naprosyn and Anaprox. Finally, there is a single medication mentioned under Tolmetin called Tolectin.*

This text describes the serious and other side effects associated with a certain medication. The serious side effects include heart attack, stroke, high blood pressure, heart failure, kidney problems, bleeding and ulcers in the stomach and intestine, low red blood cells, life-threatening skin reactions and allergic reactions, liver problems and asthma attacks. Other side effects include stomach pain, constipation, diarrhea, gas, heartburn, nausea, vomiting, and dizziness.*

This is a table presenting the mean pharmacokinetic parameters of Nabumetone Active Metabolite (6MNA) at steady state following oral administration of 1,000-mg or 2,000-mg doses of Nabumetone in young adults, elderly, and another group that is not identified. It includes units of measurement and the number of individuals in each group. The abbreviations used are Trax, typ, Clgg/F, and Vdg/F. This information appears to be part of a scientific study or report.*

This is a table showing the mean/mode duration of Nabumetone treatment for patients with Rheumatoid Arthritis and Osteoarthritis for different doses of the drug. The table also lists the number of patients who received the drug and their respective duration of treatment. It appears to be clinical trial data.*